Suppr超能文献

泰国格雷夫斯病的诊断与管理:当前实践调查

Diagnosis and Management of Graves' Disease in Thailand: A Survey of Current Practice.

作者信息

Sriphrapradang Chutintorn

机构信息

Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.

出版信息

J Thyroid Res. 2020 May 11;2020:8175712. doi: 10.1155/2020/8175712. eCollection 2020.

Abstract

BACKGROUND

The data on clinical practice patterns in the evaluation and management of Graves' disease (GD) are limited in Asia. The aims of this survey were to report the current practices in the management of GD in Thailand and to examine any international differences in the management of GD.

METHODS

Members of the Endocrine Society of Thailand who were board certified in endocrinology ( = 392) were invited to participate in an electronic survey on the management of GD using the same index case and questionnaire as in previous North American and European surveys.

RESULTS

One hundred and twenty responses (30.6%) from members were included. TSH receptor antibody measurement (29.2%), thyroid ultrasound (6.7%), and isotopic studies (5.9%) were used less frequently to confirm the etiology compared with those in North American and European surveys. Treatment with an antithyroid drug (ATD) was the preferred first choice of therapy (90.8%). Methimazole at 10-15 mg/day with a beta-blocker was the initial treatment of choice. The preferred ATD in pregnancy was propylthiouracil in the first trimester and methimazole in the second and third trimesters, which was similar to the North American and European surveys.

CONCLUSION

Ultrasound and isotopic studies will be requested only by a small proportion of Thai endocrinologists. Higher physician preference for ATD is similar to Europe, Latin America, and other Asian countries. Geographical differences in the use of ATD, radioactive iodine, and thyroidectomy exist.

摘要

背景

亚洲关于格雷夫斯病(GD)评估与管理的临床实践模式数据有限。本次调查旨在报告泰国GD管理的当前实践情况,并研究GD管理方面的国际差异。

方法

邀请泰国内分泌学会中获得内分泌学委员会认证的成员(n = 392)参与一项关于GD管理的电子调查,使用与之前北美和欧洲调查相同的索引病例和问卷。

结果

纳入了成员的120份回复(30.6%)。与北美和欧洲调查相比,促甲状腺素受体抗体测量(29.2%)、甲状腺超声(6.7%)和同位素研究(5.9%)在病因确认中的使用频率较低。抗甲状腺药物(ATD)治疗是首选的初始治疗方法(90.8%)。初始治疗选择为每天10 - 15毫克甲巯咪唑加用β受体阻滞剂。孕期首选的ATD在孕早期是丙硫氧嘧啶,孕中期和孕晚期是甲巯咪唑,这与北美和欧洲调查相似。

结论

只有一小部分泰国内分泌科医生会要求进行超声和同位素研究。医生对ATD的较高偏好与欧洲、拉丁美洲及其他亚洲国家相似。在ATD、放射性碘和甲状腺切除术的使用上存在地域差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea7c/7238361/00a4e30665b8/JTR2020-8175712.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验